1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2020, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 8, 17, 8, 2, 13, 9 and 6 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.
Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionHypercholesterolemia - Overview
Hypercholesterolemia - Therapeutics Development
Hypercholesterolemia - Therapeutics Assessment
Hypercholesterolemia - Companies Involved in Therapeutics Development
Hypercholesterolemia - Drug Profiles
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Hypercholesterolemia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2020
- Hypercholesterolemia - Pipeline by AD Pharmaceuticals Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2020
- Hypercholesterolemia - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Hypercholesterolemia - Pipeline by Amgen Inc, H2 2020
- Hypercholesterolemia - Pipeline by Amryt Pharma Plc, H2 2020
- Hypercholesterolemia - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020
- Hypercholesterolemia - Pipeline by Astellas Pharma Inc, H2 2020
- Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2020
- Hypercholesterolemia - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by BioLingus AG, H2 2020
- Hypercholesterolemia - Pipeline by CardioPharma Inc, H2 2020
- Hypercholesterolemia - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020
- Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
- Hypercholesterolemia - Pipeline by Civi Biopharma Inc, H2 2020
- Hypercholesterolemia - Pipeline by Cumberland Pharmaceuticals Inc, H2 2020
- Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Delivra Corp, H2 2020
- Hypercholesterolemia - Pipeline by Dogma Therapeutics Inc, H2 2020
- Hypercholesterolemia - Pipeline by Draupnir Bio Aps, H2 2020
- Hypercholesterolemia - Pipeline by Eight Plus One Pharmaceutical Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H2 2020
- Hypercholesterolemia - Pipeline by Gruthan Bioscience LLC, H2 2020
- Hypercholesterolemia - Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Hingez Therapeutics Inc, H2 2020
- Hypercholesterolemia - Pipeline by Innovent Biologics Inc, H2 2020
- Hypercholesterolemia - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by JW Pharmaceutical Corp, H2 2020
- Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H2 2020
- Hypercholesterolemia - Pipeline by Kowa Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2020
- Hypercholesterolemia - Pipeline by LIB Therapeutics LLC, H2 2020
- Hypercholesterolemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2020
- Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H2 2020
- Hypercholesterolemia - Pipeline by Luye Pharma Group Ltd, H2 2020
- Hypercholesterolemia - Pipeline by Lyndra Therapeutics Inc., H2 2020
- Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, H2 2020
- Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H2 2020
- Hypercholesterolemia - Dormant Projects, H2 2020
- Hypercholesterolemia - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Hypercholesterolemia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AD Pharmaceuticals Co Ltd
- Akcea Therapeutics Inc
- Alexion Pharmaceuticals Inc
- Amgen Inc
- Amryt Pharma Plc
- Arrowhead Pharmaceuticals Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Beijing Mabworks Biotech Co Ltd
- BioLingus AG
- CardioPharma Inc
- Centeer BioTherapeutics Ltd Co
- Chong Kun Dang Pharmaceutical Corp
- Civi Biopharma Inc
- Cumberland Pharmaceuticals Inc
- Daewoong Co Ltd
- Delivra Corp
- Dogma Therapeutics Inc
- Draupnir Bio Aps
- Eight Plus One Pharmaceutical Co Ltd
- Golden Biotechnology Corp
- Gruthan Bioscience LLC
- Guangzhou Jiayue Pharmaceutical Technology Co Ltd
- Hingez Therapeutics Inc
- Innovent Biologics Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JW Pharmaceutical Corp
- Kadmon Corp LLC
- Kowa Co Ltd
- Kyorin Pharmaceutical Co Ltd
- LIB Therapeutics LLC
- Lipigon Pharmaceuticals AB
- LipimetiX Development Inc
- Luye Pharma Group Ltd
- Lyndra Therapeutics Inc.
- Madrigal Pharmaceuticals Inc
- Medlab Clinical Ltd
- NeuroBo Pharmaceuticals Inc
- Novartis AG
- Novo Nordisk AS
- Nyrada Inc
- OliPass Corporation
- Pfizer Inc
- Precision Biosciences Inc
- Progenra Inc
- Regeneron Pharmaceuticals Inc
- Repair Biotechnologies Inc
- Sanofi
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen HighTide Biopharmaceutical Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shifa Biomedical Corp
- Viking Therapeutics Inc
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Teruisi Pharmaceutical Co Ltd
